Clinical Trials Browser

Congenital Bone Marrow Failure Syndromes × Imatinib Mesylate × 90 days × Clear all

NCT06090669 2026-02-17

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Phase 1 Recruiting

Classical hematology

Congenital Bone Marrow Failure Syndromes